| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018305695 |
| P356 | DOI | 10.1007/S11154-015-9320-5 |
| P698 | PubMed publication ID | 26373946 |
| P50 | author | Eberhard Nieschlag | Q86166779 |
| P2093 | author name string | Elena Vorona | |
| P2860 | cites work | Cause and manner of death among users of anabolic androgenic steroids | Q73370962 |
| Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone | Q73683927 | ||
| [Cardiomyopathy associated with uncontrolled self medication of anabolic steroids] | Q74296149 | ||
| [Cardiovascular side effects of anabolic-androgenic steroids] | Q79227577 | ||
| Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use | Q82247419 | ||
| Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids | Q84872467 | ||
| Bilateral deltoid myositis ossificans in a weightlifter using anabolic steroids | Q85886351 | ||
| Annual banned-substance review: analytical approaches in human sports drug testing | Q86417590 | ||
| The Effect of Chronic Anabolic-Androgenic Steroid Use on Tp-E Interval, Tp-E/Qt Ratio, and Tp-E/Qtc Ratio in Male Bodybuilders | Q86619506 | ||
| Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature | Q24672167 | ||
| Androgen abuse in athletes: detection and consequences | Q28272653 | ||
| Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement | Q30409171 | ||
| A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids | Q30730560 | ||
| Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. | Q33312408 | ||
| Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point | Q33615967 | ||
| Long-term anabolic androgenic steroid use is associated with increased atrial electromechanical delay in male bodybuilders. | Q33634636 | ||
| Potential adverse effects of long-term testosterone therapy | Q33637793 | ||
| Testosterone and other anabolic steroids as cardiovascular drugs. | Q33698024 | ||
| Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications | Q33872639 | ||
| Use of androgens in patients with renal failure | Q33877486 | ||
| Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids. | Q33878751 | ||
| Cardiac and Metabolic Effects of Anabolic-Androgenic Steroid Abuse on Lipids, Blood Pressure, Left Ventricular Dimensions, and Rhythm | Q33952427 | ||
| Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis | Q33975025 | ||
| Anabolic androgenic steroids: a survey of 500 users | Q33995670 | ||
| Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function | Q34015823 | ||
| The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. | Q34062583 | ||
| Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use. | Q34067706 | ||
| Effects of long term supplementation of anabolic androgen steroids on human skeletal muscle | Q34160098 | ||
| Side effects of AAS abuse: an overview. | Q34173821 | ||
| Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. | Q34433056 | ||
| Anabolic androgenic steroids and violent offending: confounding by polysubstance abuse among 10,365 general population men. | Q34435907 | ||
| MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions | Q34468501 | ||
| Androgenic steroid effects on liver and red cells | Q34676817 | ||
| Side effects of anabolic androgenic steroids abuse. | Q34713849 | ||
| Use of doping agents, particularly anabolic steroids, in sports and society | Q34783150 | ||
| Cholestatic jaundice, acute kidney injury and acute pancreatitis secondary to the recreational use of methandrostenolone: a case report | Q34818195 | ||
| Clinical features of muscle dysmorphia among males with body dysmorphic disorder | Q35116458 | ||
| Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males | Q35243264 | ||
| Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). | Q35328774 | ||
| Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? | Q35582363 | ||
| Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report | Q35634422 | ||
| Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review | Q35710533 | ||
| Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: A review. | Q35710568 | ||
| Abuse of supraphysiologic doses of anabolic steroids | Q36162216 | ||
| Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report. | Q36169231 | ||
| Inflammatory dilated cardiomyopathy (DCMI). | Q36260788 | ||
| National Athletic Trainers' Association position statement: anabolic-androgenic steroids | Q36299949 | ||
| The athlete's heart and hypertrophic cardiomyopathy: two conditions which may be misdiagnosed and coexistent. Which parameters should be analysed to distinguish one disease from the other? | Q36462899 | ||
| Performance-enhancing drugs on the web: a growing public-health issue | Q36626914 | ||
| Sex hormones and risk of liver tumor. | Q36721763 | ||
| Safety aspects of androgen treatment with 5alpha-dihydrotestosterone | Q37030903 | ||
| Eating disorders and anabolic androgenic steroids in males--similarities and differences in self-image and psychiatric symptoms | Q37116369 | ||
| Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature | Q37145641 | ||
| Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations | Q37310024 | ||
| Ethnic variation in allele distribution of the androgen receptor (AR) (CAG)n repeat | Q37323212 | ||
| Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. | Q37566952 | ||
| Sexual orientation and anabolic-androgenic steroids in U.S. adolescent boys | Q37602504 | ||
| Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient | Q37611627 | ||
| Genes in sport and doping. | Q37621203 | ||
| Doping and thrombosis in sports | Q37971351 | ||
| Genetics of hypertrophic and dilated cardiomyopathy | Q37978946 | ||
| The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis | Q38192309 | ||
| Anabolic agents: recent strategies for their detection and protection from inadvertent doping | Q38196263 | ||
| Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis | Q38241416 | ||
| Testosterone therapy and cardiovascular risk: advances and controversies | Q38338216 | ||
| Testosterone induces apoptosis in cardiomyocytes by increasing proapoptotic signaling involving tumor necrosis factor-α and renin angiotensin system. | Q38910581 | ||
| Current implementation and future of the Athlete Biological Passport | Q39579963 | ||
| Rhabdomyolysis of the deltoid muscle in a bodybuilder using anabolic-androgenic steroids: a case report | Q40398416 | ||
| Anabolic steroid-induced cardiomyopathy underlying acute liver failure in a young bodybuilder | Q41336657 | ||
| Anabolic‐Androgenic steroid abuse in weight lifters: Evidence for activation of the hemostatic system | Q41679561 | ||
| Myocardial scar detected by cardiovascular magnetic resonance in a competitive bodybuilder with longstanding abuse of anabolic steroids | Q42142706 | ||
| Anabolic androgenic steroid-induced cardiomyopathy, stroke and peripheral vascular disease | Q42153349 | ||
| Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. | Q42626533 | ||
| Neuroprotective strategies in drug abuse-evoked encephalopathy | Q42969550 | ||
| The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study | Q43172708 | ||
| Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases | Q43718026 | ||
| The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. | Q43852953 | ||
| Contraceptive steroids influence the hemostatic activation state in healthy men. | Q44028590 | ||
| A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids | Q44829950 | ||
| Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids | Q45049511 | ||
| Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen | Q45250130 | ||
| Caution for anabolic androgenic steroid use: a case report of multiple organ dysfunction syndrome | Q45265056 | ||
| Effect of testosterone on the in vitro proliferation of bone marrow granulocyte-macrophage cells (CFU-GM). II. Observations in hypogonadal subjects | Q45346909 | ||
| Multisubstance use as a feature of addiction to anabolic-androgenic steroids | Q46139036 | ||
| Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men. | Q46153377 | ||
| Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine | Q46182317 | ||
| Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits | Q46232609 | ||
| Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids | Q46495637 | ||
| Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment | Q46681488 | ||
| Effects of oxandrolone, an anabolic steroid, on hemostasis | Q46908418 | ||
| Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and population relationships | Q47233293 | ||
| Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study | Q47266806 | ||
| Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial | Q48121565 | ||
| A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: a focus on mental health. | Q50712679 | ||
| Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. | Q50886876 | ||
| Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? | Q50921771 | ||
| Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. | Q53097713 | ||
| Self-Reported Anabolic-Androgenic Steroids Use and Musculoskeletal Injuries | Q56929135 | ||
| Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid | Q57150018 | ||
| Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients | Q57316581 | ||
| Androgens and Bone | Q57606357 | ||
| Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases | Q59567827 | ||
| Effects of Anabolic-Androgenic Steroids on Muscular Strength | Q67901483 | ||
| [Dilated cardiomyopathy in a user of anabolic steroids] | Q70727590 | ||
| Is methyltestosterone no longer used therapeutically? | Q70870130 | ||
| Effect of testosterone enanthate on hematopoiesis in normal men | Q71763593 | ||
| Anabolic steroid use as the possible precipitant of dilated cardiomyopathy | Q73209602 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 199-211 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Reviews in Endocrine and Metabolic Disorders | Q15766899 |
| P1476 | title | Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions | |
| P478 | volume | 16 |
| Q53688645 | Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review. |
| Q93071124 | Anabolic-androgenic steroids and cardiovascular risk |
| Q52590789 | Defining the Construct of Synthetic Androgen Intoxication: An Application of General Brain Arousal. |
| Q38677404 | Do anabolic-androgenic steroids have performance-enhancing effects in female athletes? |
| Q39307576 | Drug-induced Liver Injury: The Hepatic Pathologist's Approach |
| Q30235442 | Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis |
| Q96233929 | Immunohistomorphometric and Hormonal Analysis of the Pituitary Gonadotropic Cells After Application of the Nandrolone Decanoate and Swimming Training in Adult Male Rats |
| Q37064717 | Impact of chronic administration of anabolic androgenic steroids and taurine on blood pressure in rats |
| Q91785381 | Knowledge of and Attitudes Toward the Use of Anabolic-Androgenic Steroids among the Population of Jeddah, Saudi Arabia |
| Q48212432 | Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities |
| Q52317326 | Molecularly imprinted polymers for the detection of illegal drugs and additives: a review. |
| Q38891192 | Novel concepts in the aetiology of male reproductive impairment |
| Q47554710 | Rhabdomyolysis in a Patient Taking Both Oxandrolone for Bodybuilding and Methamphetamine |
| Q92568515 | Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents |
| Q51040629 | Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns. |
| Q57480851 | The History of Testosterone and The Testes: From Antiquity to Modern Times |
| Q91961365 | Therapeutic significance of β-glucuronidase activity and its inhibitors: A review |
| Q47379788 | Tracking internet interest in anabolic-androgenic steroids using Google Trends |
| Q49563324 | Would male hormonal contraceptives affect cardiovascular risk? |
Search more.